Drug evaluation: STA-4783--enhancing taxane efficacy by induction of Hsp70.
Mathias Gehrmann · PubMed · 2006
The apoptosis stimulator STA-4783 acts by inducing expression of heat shock protein (Hsp)70 on tumor cell surfaces and disrupting the cytoskeletal network. Currently in development by Synta Pharmaceuticals for the potential treatment of solid tumors, phase II clinical trials in non-small-cell lung cancer, melanoma and sarcoma have been initiated.